PYC Therapeutics

About

PYC Therapeutics develops RNA-based therapies for inherited retinal diseases, advancing three candidates including lead program VP-001 targeting retinitis pigmentosa type 11 (RP11).

Mission

PYC Therapeutics is advancing RNA therapies for inherited retinal disease, including a program aimed at retinitis pigmentosa type 11 (RP11). The company is progressing three therapeutic candidates, with lead candidate VP-001 positioned as a potential first treatment for RP11. RP11 is described as a form of retinitis pigmentosa that causes blindness beginning in childhood and progressing to legal blindness by middle age. To support development, PYC has launched a capital raise and has secured AU$40 million so far of an anticipated AU$74 million round. The AU$74 million target converts to roughly US$48.6 million, and the funds are intended to advance its three candidates, including VP-001.

Quick Facts